NEWS

We inform you about the current business development of HAEMATO AG and about our investor relations activities.

Annual Report 2018

In consideration of the IFRS 15 "Revenues", which is mandatory from the financial year 2018, HAEMATO AG generated IFRS Group sales of EUR 274.1 million, an operating result (EBIT) of EUR 8.5 million and a net income of EUR 6.3 million. In the second half of 2018, as a...

read more

2018: Preliminary IFRS results

HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 274.1m (previous year: EUR 289.4m), an operating...

read more

IFRS Third-Quarter 2018 Results

In the third quarter of 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.12 million (previous year: EUR 72.5 million). In the considered period of January till September 2018 the sales amounted to € 212.8 million...

read more

Half Year Report 2018

In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 million. EBIT amounted to kEUR 6,484.6 (prior year period: kEUR 3,182.8). The consolidated profit as of 30.06.2018 amounts to kEUR 5,044.5 and is therefore also...

read more

IFRS results Q1 2018

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the...

read more

HAEMATO AG

HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag